Publications by authors named "Sindhuja Koppu"
Article Synopsis
- - Bimekizumab is a new treatment for moderate-to-severe psoriasis that selectively inhibits interleukin (IL) 17, which plays a key role in activating other interleukins linked to psoriasis symptoms.
- - A literature review of clinical trials found that bimekizumab showed better effectiveness than placebo and other treatments like ustekinumab and adalimumab.
- - Overall, bimekizumab is seen as a promising and tolerable option for managing moderate-to-severe plaque psoriasis.
Psoriasis is the result of uncontrolled keratinocyte proliferation, and its pathogenesis involves the dysregulation of the immune system. The interplay among cytokines released by dendritic, T1, T2, and T17 cells leads to the phenotypical manifestations seen in psoriasis. Biological therapies target the cytokine-mediated pathogenesis of psoriasis and have improved patient quality of life.
View Article and Find Full Text PDF